National Drug Strategy
National Drug Strategy

National Drug Strategy 2010-2015 Roundtable Consultation Report

5.5 Priorities

prev pageTOC |next page

Many participants had the view that it would be better to re-position the priority areas within the NDS as actions, which link directly to the objectives. Within that context, participants thought that the priorities would be better understood if they were written with more clarity and precision.

There was a widespread view of the need for the NDS to better reflect the key sub-strategies relating to alcohol, tobacco, illicit and licit (include pharmaceutical medicines) drugs.

Participants raised the need for the NDS to recognise its support of innovation, particularly with regards to treatment across areas where there was an existing gap in evidence.

Other key issues raised by the participants included: